293 related articles for article (PubMed ID: 35928283)
21. The role of DYRK1A in neurodegenerative diseases.
Wegiel J; Gong CX; Hwang YW
FEBS J; 2011 Jan; 278(2):236-45. PubMed ID: 21156028
[TBL] [Abstract][Full Text] [Related]
22. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.
Hawley LE; Prochaska F; Stringer M; Goodlett CR; Roper RJ
Pharmacol Biochem Behav; 2022 Jun; 217():173404. PubMed ID: 35576991
[TBL] [Abstract][Full Text] [Related]
23. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
[TBL] [Abstract][Full Text] [Related]
24. Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.
Ryu YS; Park SY; Jung MS; Yoon SH; Kwen MY; Lee SY; Choi SH; Radnaabazar C; Kim MK; Kim H; Kim K; Song WJ; Chung SH
J Neurochem; 2010 Nov; 115(3):574-84. PubMed ID: 20456003
[TBL] [Abstract][Full Text] [Related]
25. Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome.
Park J; Yang EJ; Yoon JH; Chung KC
Mol Cell Neurosci; 2007 Oct; 36(2):270-9. PubMed ID: 17720532
[TBL] [Abstract][Full Text] [Related]
26. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease.
Ryoo SR; Jeong HK; Radnaabazar C; Yoo JJ; Cho HJ; Lee HW; Kim IS; Cheon YH; Ahn YS; Chung SH; Song WJ
J Biol Chem; 2007 Nov; 282(48):34850-7. PubMed ID: 17906291
[TBL] [Abstract][Full Text] [Related]
27. From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach.
Sukreet S; Rafii MS; Rissman RA
Alzheimers Dement (Amst); 2024; 16(2):e12580. PubMed ID: 38623383
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's Disease Associated Genes Ankyrin and Tau Cause Shortened Lifespan and Memory Loss in
Higham JP; Malik BR; Buhl E; Dawson JM; Ogier AS; Lunnon K; Hodge JJL
Front Cell Neurosci; 2019; 13():260. PubMed ID: 31244615
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.
Souchet B; Audrain M; Billard JM; Dairou J; Fol R; Orefice NS; Tada S; Gu Y; Dufayet-Chaffaud G; Limanton E; Carreaux F; Bazureau JP; Alves S; Meijer L; Janel N; Braudeau J; Cartier N
Acta Neuropathol Commun; 2019 Mar; 7(1):46. PubMed ID: 30885273
[TBL] [Abstract][Full Text] [Related]
30. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
Frost D; Meechoovet B; Wang T; Gately S; Giorgetti M; Shcherbakova I; Dunckley T
PLoS One; 2011 May; 6(5):e19264. PubMed ID: 21573099
[TBL] [Abstract][Full Text] [Related]
31. Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.
Kay LJ; Smulders-Srinivasan TK; Soundararajan M
Adv Protein Chem Struct Biol; 2016; 105():127-71. PubMed ID: 27567487
[TBL] [Abstract][Full Text] [Related]
32. Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.
Jin N; Yin X; Gu J; Zhang X; Shi J; Qian W; Ji Y; Cao M; Gu X; Ding F; Iqbal K; Gong CX; Liu F
J Biol Chem; 2015 Jun; 290(24):15219-37. PubMed ID: 25918155
[TBL] [Abstract][Full Text] [Related]
33. DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome.
Feki A; Hibaoui Y
Brain Sci; 2018 Oct; 8(10):. PubMed ID: 30332747
[TBL] [Abstract][Full Text] [Related]
34. Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes.
Choi M; Kim AK; Ham Y; Lee JY; Kim D; Yang A; Jo MJ; Yoon E; Heo JN; Han SB; Ki MH; Lee KS; Cho S
Phytomedicine; 2021 Nov; 92():153695. PubMed ID: 34500300
[TBL] [Abstract][Full Text] [Related]
35. New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome.
Park J; Chung KC
Exp Neurobiol; 2013 Dec; 22(4):244-8. PubMed ID: 24465139
[TBL] [Abstract][Full Text] [Related]
36. DYRK1A inhibition as potential treatment for Alzheimer's disease.
Stotani S; Giordanetto F; Medda F
Future Med Chem; 2016 Apr; 8(6):681-96. PubMed ID: 27073990
[TBL] [Abstract][Full Text] [Related]
37. DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
Pathak A; Rohilla A; Gupta T; Akhtar MJ; Haider MR; Sharma K; Haider K; Yar MS
Eur J Med Chem; 2018 Oct; 158():559-592. PubMed ID: 30243157
[TBL] [Abstract][Full Text] [Related]
38. The Down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4.
Sitz JH; Baumgärtel K; Hämmerle B; Papadopoulos C; Hekerman P; Tejedor FJ; Becker W; Lutz B
Neuroscience; 2008 Dec; 157(3):596-605. PubMed ID: 18938227
[TBL] [Abstract][Full Text] [Related]
39. Rodent Modeling of Alzheimer's Disease in Down Syndrome:
Farrell C; Mumford P; Wiseman FK
Front Neurosci; 2022; 16():909669. PubMed ID: 35747206
[TBL] [Abstract][Full Text] [Related]
40. APP and DYRK1A regulate axonal and synaptic vesicle protein networks and mediate Alzheimer's pathology in trisomy 21 neurons.
Wu CI; Vinton EA; Pearse RV; Heo K; Aylward AJ; Hsieh YC; Bi Y; Adeleye S; Fancher S; Duong DM; Seyfried NT; Schwarz TL; Young-Pearse TL
Mol Psychiatry; 2022 Apr; 27(4):1970-1989. PubMed ID: 35194165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
